Dr. Reneé de Leeuw
Dr. Reneé de Leeuw’s research goal is to understand how cancer progression and therapeutic resistance occur and define new means to treat aggressive disease. Her graduate training, completed at the Netherlands Cancer Institute, focused on the role for phosphorylation of Serine 305 of the estrogen receptor in tamoxifen resistance in breast cancer. In her postdoctoral studies at Thomas Jefferson University in Philadelphia, she investigated how the RB tumor suppressor can be leveraged to define therapy for advanced prostate cancer patients. In Dr. Leeuw’s lab, she is utilizing her knowledge in hormone receptor and cancer biology to develop a translational research program studying the role of kinase signaling in prostate cancer progression. While classical KRAS-activating mutations are rarely observed in prostate cancer, other alterations in the MAPK pathway are common, including gene amplifications and BRAF fusions. The central aim is to assess the biological implications of clinically observed MAPK alterations for therapeutic response and aggressiveness of disease in order to develop novel biomarkers and treatment strategies that will improve disease outcomes for patients with advanced prostate cancer. In addition to her research, Dr. Leeuw serves on the Associate Member Council of the AACR.
Title: Assistant Professor
College: College of Medicine
Program: Translational Oncology Program
Member Type:Research Member